Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex

Calliditas wins the 2020 SwedenBio Award

Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021

Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report

Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial

Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020

The 200[th] patient’s last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020

First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon

Calliditas appoints Group General Counsel

Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report

CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas

Calliditas provides a corporate business update in the context of the Covid-19 pandemic

Calliditas strengthens its US Commercial Organization

Positive opinion received from EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the treatment of IgAN